Advertisement

Topics

March of approvals for cabozantinib continues with first-line kidney cancer nod

10:40 EDT 17 May 2018 | thePharmaLetter

French pharma firm Ipsen is trading about 2% higher in Paris today, on news that Cabometyx (cabozantinib),…

Original Article: March of approvals for cabozantinib continues with first-line kidney cancer nod

NEXT ARTICLE

More From BioPortfolio on "March of approvals for cabozantinib continues with first-line kidney cancer nod"

Advertisement
Quick Search
Advertisement
Advertisement